New Era in Melanoma

Mike Hennessy
Published: Wednesday, Sep 27, 2017
Mike Hennessy
OncLive Chairman,
Mike Hennessy
It was just 6 years ago that options for patients with metastatic melanoma began to expand. In 2011, the approval of ipilimumab (Yervoy), the pioneering checkpoint immunotherapy for patients with unresectable or metastatic disease, marked the first milestone. Clinicians treating patients with advanced melanoma now have a toolkit that is stocked with several types of immunotherapies and targeted therapies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication